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Summary. The Bcl-2 protein blocks a distal step in an 
evolutionarily conserved pathway for programmed cell 
death and apoptosis. The gene encoding this protein was 
first discovered because of its involvement in the 
t(14;18) chromosomal translocations commonly found in 
B-cell lymphomas. Overexpression of Bcl-2 also occurs 
in many other types of human cancers, and prevents cell 
death induced by nearly all anticancer drugs and 
radiation. Since the discovery of Bcl-2 over ten years 
ago, several cellular and viral homologs have been 
identified, some of which suppress cell death and others 
which promote apoptosis. Many of these proteins can 
interact with each other through a complex network of 
homo- and heterodimers. Though functionally important, 
dimerization events still do not explain in a broader 
sense how these proteins actually control cell life and 
death. Recent findings that Bcl-2 can function both as an 
ion channel and as an adapter or docking protein 
however are beginning to provide insights into the 
molecular mechanisms through which these proteins 
regulate the programmed cell death pathway in normalcy 
and disease. 
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Introduction 
Programmed cell death plays a critical role in normal 
development or tissue homeostasis, where it helps to 
maintain total cell numbers within physiologically 
appropriate ranges by ensuring that cell production by 
mitogenesis is offset by a commensurate amount of cell 
loss. In many cases, this form of cell death proceeds by 
apoptosis, a process that includes a characteristic set of 
morphological or biochemical features  such as  
cell shrinkage, membrane blebbing, condensation 
and segmentation of nuclei, and fragmentation of 
chromosomal DNA. Dysregulation of the physiological 
cell death process can have profound consequences, and 
probably plays a major role in.many types of diseases, 
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including cancer, autoimmune diseases, and AIDS. One 
of the best studied survival genes is bcl-2, the first 
member identified of a growing family of genes that 
participate in the control of apoptosis. 
Discovery of bcl-2 gene 
The bcl-2 (B cell lymphoma/leukemia-2) gene was 
first discovered because of its involvement in B-cell 
malignancies, where t(14;18) chromosomal trans- 
locations activate the gene in about 80-90% of follicular 
non-Hodgkin's B-cell lymphomas (Tsujimoto et al., 
1985). In these translocations, the bcl-2 gene is moved 
from its normal location on chromosome 18q21 into 
juxtaposition with the immunoglobulin heavy chain 
locus on chromosome 14q32, thus placing the bcl-2 gene 
under the influence of powerful transcriptional enhancer 
elements associated with the immunoglobulin heavy 
chain locus and leading to overproduction of bcl-2 
mRNAs and their encoded proteins. In the majority of 
cases the chromosome 18 breakpoint occur in the 3' 
untranslated region of bcl-2, thus the breakpoints of 
these t(14;18) translocations do not result typically in an 
abnormal gene product. 
The Bcl-2 protein is 239 amino acids in length in 
humans (25-26 kD) and contains no recognized motifs or 
homologies that hint at its function (Tsujimoto and 
Croce, 1986). The first description of its cellular 
function by Vaux et al. (1988) employed lymphokine 
Interleukin-3 (IL-3) dependent immature pre-B-cells for 
transfections of bcl-2. Overexpression of bcl-2 permitted 
prolonged cell survival in the absence of IL-3, but did 
not promote cell cycle progression (Vaux et al., 1988; 
Hockenbery et al., 1990). The similar results were 
obtained in IL-4- and GM-CSF-dependent cells (Nuiiez 
et al., 1990) and in certain IL-2-dependent (Deng and 
Podack, 1993) and IL-6-dependent (Schwarze and 
Hawley, 1995) cells. This findings suggest that the bcl-2 
gene defines a new category of oncogenes, unlike 
oncogenes studied previously, which functions in 
preventing programmed cell death without necessarily 
affecting cellular proliferation. Bcl-2 has also been 
found to protect against neuronal cell death induced by 
nerve growth factor (NGF) withdrawal (Batistatou et al., 
1993; Mah et al. ,  1993). Microinjection of bcl-2 









